08/06/2026
New Hampshire recently removed unnecessary barriers to treatment of ADHD, narcolepsy and chronic low testosterone.
As of July 21, 2026, HB 126 allows prescriptions for stimulant medications to be filled for up to a 90-day supply. It also allows up to a 92-day supply of topical or injectable androgen prescribed for chronic low testosterone.
Patients with ADHD already live with challenges involving planning, time awareness, organization, and task completion. Requiring them to navigate a controlled-medication refill every 30 to 34 days added an administrative obstacle directly related to the condition being treated. When medication was temporarily out of stock, some patients went without treatment, with predictable effects on focus, work, school, driving, relationships, and daily functioning.
The same reasoning applies to established chronic low testosterone. A man whose body does not produce adequate testosterone will not suddenly begin producing enough because the calendar reached day 34. Low testosterone is not simply a s*x hormone...low T causes significant fatigue, depressed mood, and difficulty concentrating. When clinically appropriate, a longer supply can support continuity, adherence, symptom control, and a more efficient prescribing workflow.
One important caveat: HB 126 permits longer fills, but it does not guarantee that every insurer or pharmacy will dispense the full amount.
If a pharmacy cannot fill the prescription as written, contact your prescriber promptly and provide the name and contact information of an alternate pharmacy that has confirmed availability. If insurance is the barrier, call the member-services or pharmacy-benefit number on your insurance card. For an employer-sponsored plan, HR or your benefits administrator may also be able to clarify plan restrictions.
The legislators that put forth this bill wanted to protect patients without creating needless barriers to appropriate care. HB 126 is a welcome improvement for New Hampshire patients and the clinicians who care for them.
